The Florida-based biopharmaceutical firm confirmed that the trial successfully validated the safety and tolerability of its soft mist technology. By achieving predefined performance limits, the study provides a foundation for the company to accelerate its development pipeline, which currently targets conditions ranging from pulmonary fibrosis to obesity and central nervous system disorders.
In section Releases
TranspireBio Validates Springboard Soft Mist Inhaler in Phase 1 Study
A pivotal pharmacokinetic trial for TranspireBio’s proprietary Springboard Soft Mist Inhaler has met all primary and secondary endpoints, demonstrating low within-subject variability. The results confirm the platform’s capacity for consistent drug delivery, marking a critical step toward the company's goal of expanding its portfolio of inhaled therapeutic options.
Dr. Xian-Ming Zeng, Chief Executive Officer of TranspireBio, highlighted that the success of the Springboard platform underscores the company's internal capabilities in high-end inhalation manufacturing. To support future commercialization, the company is preparing to scale its production infrastructure. While current operations are centered in Weston, TranspireBio has scheduled the opening of a new manufacturing facility in Pembroke Pines for 2028.
Comments (0)
No comments yet. Be the first!